21st Austria weekly - Valneva Warimpex RHI Magnesita 30/05/2023 [pic1]Valneva: Valneva. an Austrian/French specialty vaccine company today announces the filing of a regulatory application with Health Canada for marketing approval Company’s single-shot chikungunya candidate VLA1553 in persons aged 18 years and above. This is second VLA1553 filed by Company intends to make additional submissions 2023.Valneva: performance: -3.30% Warimpex: The business operations Warimpex Group
21st Austria weekly - Valneva Lenzing 14/02/2023 [pic1]Valneva: an Austrian/French specialty vaccine company announced that it completed enrollment and vaccination for a Phase 3 trial in adolescents VLA1553-321 of its single-shot chikungunya candidate VLA1553. First results the are expected mid-2023. The VLA1553-321 adolescent is also to support licensure Europe Brazil which would be first potential approval use endemic populations. Brazil had exponential increase cases 2021 comparison 2020 according data from Brazilian Vigilance Health Secretary
21st Austria weekly - Valneva Vienna Stock Exchange 30/12/2022 [pic1]Valneva: an Austrian/French specialty vaccine company reported further heterologous booster data from exploratory small clinical study for its inactivated COVID-19 vaccine VLA2001. The show that a dose of VLA2001 was well tolerated in previously BNT162b2 Pfizer/BioNTech- or mRNA 1273 Moderna-vaccinated participants confirming the favorable safety profile seen across all studies – including homologous settings. However this study additional elicited only marginally increased neutralizing antibody response. Company positive results following primary vaccination with ChAdOx1-S AstraZeneca August
21st Austria weekly - Valneva Agrana 30/09/2022 [pic1]Valneva: Valneva SE an Austrian/French specialty vaccine company announced the pricing of 21 000 000 ordinary shares in a global offering to specified categories investors comprised public 375 000 American Depositary Shares “ADSs” each representing two shares United States and concurrent private placement 20 250 000 shares. The price was set at Euro 4.90 per share corresponding USD 9.51 ADS. As result excess demand Company
21st Austria weekly - Valneva Pierer Mobility 16/09/2022 [pic1]Valneva: an Austrian/French specialty vaccine company and IDT Biologika today announced they have agreed to terminate their collaboration following the delivery of inactivated COVID-19 bulk considering current order levels existing inventories. In light reduced European Commission order Valneva has suspended manufacturing and as compensation will pay up Euro 36.2 mn in cash equivalent 4.5 kind form specified equipment purchased by Valneva.As per commercial services agreement signed November 2021 produced VLA2001 at its Biosafety Level